Terms: = Kidney tumors AND ABL2, ARG, 27, ENSG00000143322, P42684, ABLL, RP11-177A2_3 AND Treatment
10952 results:
1. Current State of Liver Transplantation for Cholangiocarcinoma: A Comprehensive Literature Review.
Mansoor J; Heaton N; Junaid Z
Exp Clin Transplant; 2024 Mar; 22(3):167-179. PubMed ID: 38695585
[TBL] [Abstract] [Full Text] [Related]
2. Epidemiology, treatment and outcomes of primary renal sarcomas in adult patients.
Uhlig J; Uhlig A; Deshpande H; Ströbel P; Trojan L; Lotz J; Hurwitz M; Hafez O; Humphrey P; Grünwald V; Kim HS
Sci Rep; 2024 May; 14(1):10038. PubMed ID: 38693188
[TBL] [Abstract] [Full Text] [Related]
3. A retrospective clinical analysis of 11 cases of PEComa from different sites.
Yan J; Zhou D; Wang Y; Yang B; Wang Y; Zhang K; Zhang S; Zhang B; Meng Q; Lv Q
World J Surg Oncol; 2024 Apr; 22(1):116. PubMed ID: 38689335
[TBL] [Abstract] [Full Text] [Related]
4. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma.
Rahman SN; Long JB; Westvold SJ; Leapman MS; Spees LP; Hurwitz ME; McManus HD; Gross CP; Wheeler SB; Dinan MA
JAMA Netw Open; 2024 Apr; 7(4):e248747. PubMed ID: 38687479
[TBL] [Abstract] [Full Text] [Related]
5. Patient's self-reported quality of life as a prognostic factor in metastatic renal cell carcinoma initially treated with TKI: nomogram proposal.
Lendínez-Cano G; Vilches-Arenas Á; Congregado-Ruíz B; Medina-López R
World J Urol; 2024 Apr; 42(1):267. PubMed ID: 38678165
[TBL] [Abstract] [Full Text] [Related]
6. The Evolution of Upper Tract Urothelial Carcinoma Management in kidney Recipients.
Lin KJ; Chen SY; Chiang YJ; Chu SH; Liu KL; Lin CT; Pan PY; Wang HH
Transplant Proc; 2024 Apr; 56(3):554-556. PubMed ID: 38670734
[TBL] [Abstract] [Full Text] [Related]
7. Squamous Cell Carcinoma Arising From Epidermal Cyst: A Case Series of 9 Patients With a Literature Review.
Kim JY; Min S; Park JK; Kim SW
Ann Plast Surg; 2024 May; 92(5):575-579. PubMed ID: 38669586
[TBL] [Abstract] [Full Text] [Related]
8. Soluble Immune Checkpoint Molecules as Predictors of Efficacy in Immuno-Oncology Combination Therapy in Advanced Renal Cell Carcinoma.
Ueda K; Uemura K; Ito N; Sakai Y; Ohnishi S; Suekane H; Kurose H; Hiroshige T; Chikui K; Nishihara K; Nakiri M; Suekane S; Ogasawara S; Yano H; Igawa T
Curr Oncol; 2024 Mar; 31(4):1701-1712. PubMed ID: 38668032
[TBL] [Abstract] [Full Text] [Related]
9. Management of Nontraumatic Spontaneous Renal Hemorrhage (Wünderlich Syndrome) through Robotic-Assisted Laparoscopic Nephrectomy: A Case Series.
Tao B; Zhang H; Zhang G; Liu H; Meng L; Zhu X; Ji X; Jia G; Qi A; Wang C
Am J Case Rep; 2024 Apr; 25():e942826. PubMed ID: 38659203
[TBL] [Abstract] [Full Text] [Related]
10. [Oncological results of repeat partial nephrectomy in patients with recurrence after nephron-sparing procedures].
Matveev V B; Zhumabaev N K; Komarov M I; Klimov A V; Stilidi I S
Urologiia; 2024 Mar; (1):86-91. PubMed ID: 38650411
[TBL] [Abstract] [Full Text] [Related]
11. Comparison of skin cancer risk between renal transplant recipients and patients with glomerular diseases in rural Queensland.
Thet Z; Lam AK; Ng SK; Aung SY; Han T; Ranganathan D; Newsham S; Borg J; Pepito C; Khoo TK
Aust J Rural Health; 2024 Apr; 32(2):249-262. PubMed ID: 38646861
[TBL] [Abstract] [Full Text] [Related]
12. A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma.
Xu J; Zhang W; Tong J; Liu C; Zhang Q; Cao L; Yu J; Zhou A; Ma J
Cancer Immunol Immunother; 2024 Apr; 73(6):107. PubMed ID: 38642109
[TBL] [Abstract] [Full Text] [Related]
13. Identifying predictors of COVID-related delays in cancer-specific medical care.
Greteman BB; Del Vecchio NJ; Garcia-Auguste CJ; Kahl AR; Gryzlak BM; Chrischilles EA; Charlton ME; Nash SH
Cancer Med; 2024 Apr; 13(8):e7183. PubMed ID: 38629238
[TBL] [Abstract] [Full Text] [Related]
14. Long-term outcome of pediatric renal transplantation with donors younger than 6 years.
Ramirez-Amoros C; San Basilio M; Amesty V; Rivas S; Lobato R; Fernandez-Camblor C; Lopez-Pereira P; Martinez-Urrutia MJ
Pediatr Transplant; 2024 May; 28(3):e14761. PubMed ID: 38628086
[TBL] [Abstract] [Full Text] [Related]
15. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease.
Li H; Huntington S; Gross C; Wang SY
PLoS One; 2024; 19(4):e0300789. PubMed ID: 38625861
[TBL] [Abstract] [Full Text] [Related]
16. Development of crizotinib-associated renal cyst in a non-small cell lung cancer patient with ALK fusion: a case report and review of the literature.
Zhang P; Xu J; Wu Q; Qian J; Wang S
Diagn Pathol; 2024 Apr; 19(1):58. PubMed ID: 38616252
[TBL] [Abstract] [Full Text] [Related]
17. PSAT1 enhances the efficacy of the prognosis estimation nomogram model in stage-based clear cell renal cell carcinoma.
Wang J; He X; Mi Y; Chen YQ; Li J; Wang R
BMC Cancer; 2024 Apr; 24(1):463. PubMed ID: 38614981
[TBL] [Abstract] [Full Text] [Related]
18. Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas.
Roskoski R
Pharmacol Res; 2024 May; 203():107181. PubMed ID: 38614375
[TBL] [Abstract] [Full Text] [Related]
19. The impact of the COVID-19 pandemic on renal cancer care.
Yildirim H; Bins AD; van den Hurk C; van Moorselaar RJA; van Oijen MGH; Bex A; Zondervan PJ; Aben KKH
World J Urol; 2024 Apr; 42(1):231. PubMed ID: 38613582
[TBL] [Abstract] [Full Text] [Related]
20. treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A).
Atkins MB; Jegede OA; Haas NB; Mcdermott DF; Bilen MA; Stein M; Sosman J; Alter R; Plimack ER; Ornstein MC; Hurwitz M; Peace DJ; Einstein D; Catalano PJ; Hammers H; Regan MM
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38604810
[TBL] [Abstract] [Full Text] [Related]
[Next]